You searched for: endometrijali (Maltesiska - Engelska)

endometrijali
endometrial

effetti endometrijali
endometrial effects

iperplasija endometrijali mhux ikkurata.
untreated endometrial hyperplasia.

riskju ta’ kanċer endometrijali
endometrial cancer risk

ma hemmx evidenza ta’ proliferazzjoni endometrijali.
there is no evidence of endometrial proliferation.

ipertrofija endometrijalia(ħxuna endometrijali sonografika)
endometrial hypertrophya (sonographic endometrial thickness)

storja ta’ iperplasija endometrijali (ara hawn taħt)
a history of endometrial hyperplasia (see below)

rakkomandazzjonijiet dettaljati għall-ġestjoni tat-tixħin endometrijali
detailed recommendations for management of endometrial thickening.

dawn il-bidliet ma għandhomx jiġu mfixkla ma’ iperplażja endometrijali.
these changes should not be confused with endometrial hyperplasia.

jekk għandek ħxuna eċċessiva tar-rita tal-utru, bħal iperplasija endometrijali.
if you have excessive thickening of the womb lining, such as endometrial hyperplasia.

hemm riskju ta’ żieda fit-tibdil endometrijali fosthom iperplasja, polipi u kanċer.
there is a risk of increased endometrial changes including hyperplasia, polyps and cancer.

bidu ta’ wġigħ ta’ ras tat-tip bħall-emigranja iperplasija u karċinoma endometrijali
new onset of migraine-type headache endometrial hyperplasia and carcinoma

barra minn hekk, bidliet riversibbli lill-endometriju huma indikati bħala paec u huma differenti minn iperplażja endometrijali.
in addition, reversible changes to the endometrium are denoted paec and are different from endometrial hyperplasia.

- id- dejta tas- sigurtà endometrijali mhix konformi mal- linja gwida ewropea dwar l -
- the endometrial safety data is not in accordance with the european guideline on clinical

ipertrofija endometrijali tista’ sseħħ waqt il-kura minħabba l-effett estroġeniku parzjali ta’ toremifene.
endometrial hypertrophy may develop during the treatment due to the partial estrogenic effect of toremifene.

ir-riskju ta’ kanċer endometrijali huwa madwar 5 minn kull 1 000 mara b’utru li ma jużawx l-hrt.
the endometrial cancer risk is about 5 in every 1,000 women with a uterus not using hrt.

it-tħaxxin endometrijali jerġa’ lura meta l-kura titwaqqaf u jerġgħu jibdew il-pirjids l-mestrwali.
the endometrial thickening reverses when treatment is stopped and menstrual periods resume.

ma hemm l-ebda evidenza tal-effetti endometrijali avversi fil-pazjenti b’kanċer tas-sider li ġew studjati.
there is no evidence of adverse endometrial effects in the breast cancer patients studied.

in-nisa li jieħdu duavive ma għandhomx jieħdu estroġeni addizzjonali għaliex dan jista’ jżid ir-riskju ta’ iperplasija endometrijali u karċinoma endometrijali.
women taking duavive should not take additional oestrogens as this may increase the risk of endometrial hyperplasia and endometrial carcinoma.

bidliet fil-kisja tal-utru (endometriju), kanċer tal-kisja tal-utru (kanċer endometrijali)
changes in the lining of the uterus (endometrium), cancer of the lining of the womb (endometrial cancer)